Iacopo Peccatori

List of Publications by Year
in descending order

160	5,222	109321	91884
papers	citations	35 h-index	69 g-index

161	161	161	6553
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Editorial: Strengths and Challenges of Allo-SCT in the Modern Era. Frontiers in Oncology, 2022, 12, 850403.	2.8	1
2	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation, 2022, 57, 1389-1398.	2.4	10
3	Microbiome markers are early predictors of acute GVHD in allogeneic hematopoietic stem cell transplant recipients. Blood, 2021, 137, 1556-1559.	1.4	18
4	Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. American Journal of Transplantation, 2021, 21, 1622-1628.	4.7	35
5	Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome. Frontiers in Immunology, 2021, 12, 670822.	4.8	0
6	The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia. International Journal of Antimicrobial Agents, 2021, 57, 106335.	2.5	9
7	Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients. Frontiers in Oncology, 2021, 11, 705568.	2.8	4
8	Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial. Frontiers in Oncology, 2021, 11, 731478.	2.8	8
9	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transplantation and Cellular Therapy, 2021, 27, 776.e1-776.e13.	1.2	26
10	Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type. Current Research in Translational Medicine, 2021, 69, 103313.	1.8	0
11	Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Postâ€transplant cyclophosphamide to overcome the HLAâ€matching barrier. Transplant Infectious Disease, 2021, 23, e13551.	1.7	0
12	Coadministration of letermovir and sirolimus in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2021, , .	2.4	1
13	Quantitative polymerase chain reaction-based chimerism in bone marrow or peripheral blood to predict acute myeloid leukemia relapse in high-risk patients: results from the KIM-PB prospective study. Haematologica, 2021, 106, 1480-1483.	3.5	5
14	Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial. Biology of Blood and Marrow Transplantation, 2020, 26, 316-322.	2.0	4
15	Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. Biology of Blood and Marrow Transplantation, 2020, 26, 1179-1188.	2.0	49
16	Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide. Frontiers in Immunology, 2019, 10, 2319.	4.8	25
17	CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS.. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019048.	1.3	9
18	Ultrasound elastography techniques for diagnosis and follow-up of hepatic veno-occlusive disease. Bone Marrow Transplantation, 2019, 54, 1145-1147.	2.4	7

#	Article	IF	Citations
19	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nature Communications, 2019, 10, 1065.	12.8	120
20	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nature Medicine, 2019, 25, 603-611.	30.7	253
21	Islet Allotransplantation in the Bone Marrow of Patients With Type 1 Diabetes: A Pilot Randomized Trial. Transplantation, 2019, 103, 839-851.	1.0	27
22	Lung Ultrasound to Evaluate Invasive Fungal Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Infection and Chemotherapy, 2019, 51, 386.	2.3	3
23	Nanosphere's VerigeneÂ® Blood Culture Assay to Detect Multidrug-Resistant Gram-Negative Bacterial Outbreak: A Prospective Study on 79 Hematological Patients in a Country with High Prevalence of Antimicrobial Resistance. Clinical Hematology International, 2019, 1, 120-123.	1.7	2
24	CMV-Specific T Cells Restricted By Shared and Donor, but Not By Host HLA Molecules Reconstitute in the First 180 Days after Allogeneic HSCT and Protect from CMV Reactivation: Results of a Prospective Observational Study. Blood, 2019, 134, 4536-4536.	1.4	0
25	Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1476-1482.	2.0	39
26	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. Bone Marrow Transplantation, 2018, 53, 1201-1205.	2.4	10
27	Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients. Bone Marrow Transplantation, 2018, 53, 410-416.	2.4	10
28	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. Bone Marrow Transplantation, 2018, 53, 1522-1531.	2.4	22
29	Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma. Bone Marrow Transplantation, 2018, 53, 213-218.	2.4	8
30	CD3+ Graft Cell Count Predicts Chronic Gvhd Incidence in Haploidentical Allogeneic Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2018, 24, S297.	2.0	0
31	First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature. Frontiers in Immunology, 2018, 9, 113.	4.8	25
32	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood, 2018, 131, 247-262.	1.4	164
33	Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study. Blood, 2018, 132, 818-818.	1.4	19
34	Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT. Blood, 2018, 132, 2028-2028.	1.4	1
35	ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience. Blood, 2018, 132, 3381-3381.	1.4	0
36	Endocrinopathies Following Allogeneic Stem Cell Transplantation: 10 Years Follow-up in 402 Patients. Blood, 2018, 132, 4600-4600.	1.4	1

#	Article	IF	Citations
37	Immune Reconstitution Is a Predictive Biomarker of Chronic Graft-Versus-Host Disease: Analysis of 307 Consecutive Patients. Blood, 2018, 132, 4579-4579.	1.4	0
38	Combining Whole Exome Sequencing and Rnaseq to Provide a Comprehensive Landscape of the Mechanisms of Post-Transplantation Leukemia Relapse. Blood, 2018, 132, 819-819.	1.4	0
39	Post-Transplant Cyclophosphamide and Sirolimus in Matched Related and Unrelated Allogeneic Transplant with a Treosulfan-Based Conditioning. Blood, 2018, 132, 4662-4662.	1.4	0
40	Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?. Expert Review of Hematology, 2017, 10, 479-492.	2.2	34
41	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. Expert Opinion on Biological Therapy, 2017, 17, 821-836.	3.1	4
42	Acquired Complement Regulatory Gene Mutations and Hematopoietic Stem Cell Transplantâ€"Related Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 2017, 23, 1580-1582.	2.0	17
43	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. American Journal of Hematology, 2017, 92, 1011-1019.	4.1	14
44	Longâ€term outcome after a treosulfanâ€based conditioning regimen for patients with acute myeloid leukemia: A report from the <scp>A</scp>cute <scp>L</scp>eukemia <scp>W</scp>orking <scp>P</scp>arty of the <scp>E</scp>uropean <scp>S</scp>ociety for <scp>B</scp>lood and <scp>M</scp>arrow <scp>T</scp>ransplantation. Cancer, 2017, 123, 2671-2679.	4.1	37
45	A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 2151-2158.	2.0	9
46	Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2017, 52, 114-119.	2.4	33
47	Enteric Microbiome Markers as Early Predictors of Clinical Outcome in Allogeneic Hematopoietic Stem Cell Transplant: Results of a Prospective Study in Adult Patients. Open Forum Infectious Diseases, 2017, 4, ofx215.	0.9	45
48	Elderly patientsâ€‰>â€‰65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs. American Journal of Hematology, 2016, 91, E302-3.	4.1	2
49	Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. Haematologica, 2016, 101, e157-e161.	3.5	55
50	Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2016, 51, 1022-1024.	2.4	6
51	Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome. Biology of Blood and Marrow Transplantation, 2016, 22, 2250-2255.	2.0	36
52	Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. Blood, 2016, 128, 1528-1531.	1.4	46
53	Autologous Islet Transplantation in Patients Requiring Pancreatectomy: A Broader Spectrum of Indications Beyond Chronic Pancreatitis. American Journal of Transplantation, 2016, 16, 1812-1826.	4.7	46
54	Secondary SOLID Tumors after Allogeneic STEM CELL Transplantation: A CROSS-Sectional Evaluation in 260 Adults at 1-Year Follow-up. Biology of Blood and Marrow Transplantation, 2016, 22, S189-S190.	2.0	0

#	Article	IF	Citations
55	Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Hematological Oncology, 2016, 34, 154-160.	1.7	6
56	Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse. Bone Marrow Transplantation, 2016, 51, 466-469.	2.4	6
57	High rate of hematological responses to sorafenib in <scp>FLT</scp>3â€<scp>ITD</scp> acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2016, 96, 629-636.	2.2	35
58	Escalated Dose-Rates of Total Marrow Irradiation (TMI) Combined with Treosulfan and Fludarabine-Based Conditioning Chemotherapy Regimen for Chemosensitive Advanced Multiple Myeloma (MM) Patients Undergoing a Matched Allogeneic Stem-Cell Transplantation: First Results of a Phase I/II Prospective Monocentric Study (TrRaMM TMI). Blood, 2016, 128, 2221-2221.	1.4	1
59	Voriconazole and Non-Melanoma Skin Cancer after Allogeneic HSCT: Results of a Prospective Dedicated Follow-up Program in 302 Patients. Blood, 2016, 128, 3442-3442.	1.4	1
60	Multiple Inhibitory Receptors Are Expressed on Central Memory and Memory Stem T Cells Infiltrating the Bone Marrow of AML Patients Relapsing after Allo-HSCT. Blood, 2016, 128, 4564-4564.	1.4	3
61	Post-Transplant Treatment with Ponatinib for Patients with High-Risk Philadelphia Chromosome Positive Leukemia. Blood, 2016, 128, 5810-5810.	1.4	1
62	Longitudinal Microbiome Profile in Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Study in 100 Patients. Blood, 2016, 128, 3435-3435.	1.4	0
63	Disease Risk Index (DRI) Score Stratification and Composite End-Point GvHD-Free Relapse-Free Survival (GRFS) May Optimize Transplant Decision-Making Process in Haploidentical Stem Cell Transplantation. Blood, 2016, 128, 3492-3492.	1.4	0
64	How to Monitor Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation: A Survey from the EBMT- Cellular Therapy & Immunobiology Working Party. Blood, 2016, 128, 4581-4581.	1.4	0
65	Pre-Transplant Colonization By a Multidrug-Resistant Gram Negative Bacteria Has No Impact on Overall Survival and Mortality after Hematopoietic Stem Cell Transplantation: A Single-Center Experience in 362 Patients. Blood, 2016, 128, 5743-5743.	1.4	0
66	Pentraxin 3 As a Novel Diagnostic and Prognostic Biomarker for Acute GvHD and Fungal Infections in Adult Allogeneic HSCT Recipients. Blood, 2016, 128, 4600-4600.	1.4	1
67	Role of Cell Source and Graft Composition in Haploidentical Transplantation Using Post-Transplant Cyclophosphamide. Blood, 2016, 128, 4664-4664.	1.4	0
68	Biomarkers Predicting Acute GvHD and Transplant Outcomes in 120 Consecutive Allogeneic HSCT Recipients. Blood, 2016, 128, 2240-2240.	1.4	0
69	HHV6 Specific T-Cells Are Predictive Biomarker of Active HHV6 Infection after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Study in 213 Patients. Blood, 2016, 128, 3399-3399.	1.4	0
70	Infection-Related Mortality (IRM) after Allogeneic Hematopoietic Stem Cell Transplantation: Age, CMV Status, Pre-Transplant IgA and IgM Levels Predict IRM and Survival in a New Clinico-Biological Scoring System Developed in 492 Consecutive Patients. Blood, 2016, 128, 2220-2220.	1.4	1
71	Natural Killer Cell Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Elimination of Donor-Derived Mature Alloreactive NK Cells, but Favorable Conditions for Adoptive Immunotherapy. Blood, 2016, 128, 4567-4567.	1.4	0
72	Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. Blood, 2015, 125, 2865-2874.	1.4	119

#	Article	IF	Citations
73	Improving the safety of cell therapy with the TK-suicide gene. Frontiers in Pharmacology, 2015, 6, 95.	3.5	102
74	Haploidentical HSCT: a 15-year experience at San Raffaele. Bone Marrow Transplantation, 2015, 50, S67-S71.	2.4	6
75	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. Biology of Blood and Marrow Transplantation, 2015, 21, 1506-1514.	2.0	121
76	Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Science Translational Medicine, 2015, 7, 317ra198.	12.4	102
77	Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia, 2015, 29, 396-405.	7.2	114
78	Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia, 2015, 29, 1143-1152.	7.2	110
79	Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall. Bone Marrow Transplantation, 2015, 50, 1262-1264.	2.4	11
80	Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predict Survival after Haploidentical Stem Cell Transplantation: A Comparative Study with EBMT Risk Score in 220 Consecutive Patients. Blood, 2015, 126, 4400-4400.	1.4	1
81	HLA Loss Leukemia Relapses after Partially-Incompatible Allogeneic HSCT As a Prototypical System to Investigate Natural Killer Cell Dynamics. Blood, 2015, 126, 743-743.	1.4	2
82	Antifungal Prophylaxis with Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Using Sirolimus for Prevention of Graft-Versus-Host Disease. Blood, 2015, 126, 4335-4335.	1.4	0
83	Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults. Blood, 2015, 126, 4362-4362.	1.4	0
84	Low-Dose Antithymocyte Globulin, Post-Transplant Cyclophosphamide and Sirolimus As Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Transplants. Blood, 2015, 126, 5465-5465.	1.4	0
85	Tracking Genetically Engineered Lymphocytes Long-Term Reveals the Dynamics of T-Cell Immunological Memory. Blood, 2015, 126, 263-263.	1.4	0
86	Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. Frontiers in Immunology, 2014, 5, 16.	4.8	126
87	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Annals of Neurology, 2014, 75, 447-453.	5.3	43
88	Wilms' Tumor Gene 1 Transcript Levels in Leukapheresis ofÂPeripheral Blood Hematopoietic Cells Predict Relapse Risk inÂPatients Autografted for Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1586-1591.	2.0	26
89	Bortezomibâ€•and thalidomideâ€induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. American Journal of Hematology, 2014, 89, 1085-1091.	4.1	45
90	Bendamustine Combined with Donor Lymphocytes Infusion in Hodgkin's Lymphoma Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1444-1447.	2.0	21

#	Article	IF	Citations
91	Autologous Pancreatic Islet Transplantation in Human Bone Marrow. Diabetes 2013;62:3523-3531. Diabetes, 2014, 63, 377-377.	0.6	0
92	Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study. Blood, 2014, 124, 196-196.	1.4	11
93	Graft-Versus-Host Disease after Haploidentical Stem Cell Transplantation in High Risk Haematological Diseases: A 10-Years Evaluation at San Raffaele Scientific Institute. Blood, 2014, 124, 2498-2498.	1.4	6
94	Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study. Blood, 2014, 124, 2535-2535.	1.4	5
95	Sirolimus and Post Transplant Cyclophosphamide (PT-Cy) Allow the Use of Haploidentical PBSC Grafts Inducing a Favorable Immune Reconstitution with Low Rates of GvHD: Results in 39 Patients. Blood, 2014, 124, 2584-2584.	1.4	1
96	Droplet Digital PCR for DNMT3A and IDH1/2 Mutations to Improve Early Diagnosis of Acute Myeloid Leukemia Relapse after Allogeneic HSCT. Blood, 2014, 124, 3951-3951.	1.4	1
97	Acute Myeloid Leukemia Relapses after Allogenenic HSCT Display a Distinctive Immune-Related Signature, with Frequent and Functionally Relevant Alterations in HLA Class II Antigen Presentation and T Cell Costimulation. Blood, 2014, 124, 427-427.	1.4	9
98	Revealing the Generation of Human Memory Stem T Cells in Haploidentical T-Replete Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 192-192.	1.4	0
99	Rapid Molecular Detection of Pathogens in 516 Consecutive Haematological Patients with Febrile Neutropenia. Blood, 2014, 124, 2750-2750.	1.4	0
100	Early Blast Clearance Evaluation after Induction Chemotherapy for Acute Myeloid Leukemia By Multiparameter Flow Cytometry and WT1-RNA Quantification: A Single Center Experience. Blood, 2014, 124, 5333-5333.	1.4	0
101	Haploidentical Hematopoietic Stem Cell Transplantation with Treosulfan-Based Conditioning Regimen for Acute Leukemia Relapsing after Initial Allogeneic Transplantation. Blood, 2014, 124, 3956-3956.	1.4	4
102	Human Herpes Virus 6 Infection in 54 Patients after Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Manifestations and Outcome. Blood, 2014, 124, 3899-3899.	1.4	0
103	Haploidentical Allogeneic Stem Cell Transplantation in Poor Risk Cytogenetic Acute Myeloide Leukemia: Results in 33 Patients. Blood, 2014, 124, 5942-5942.	1.4	0
104	Autologous Pancreatic Islet Transplantation in Human Bone Marrow. Diabetes, 2013, 62, 3523-3531.	0.6	90
105	IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood, 2013, 121, 573-584.	1.4	455
106	Post-Transplant Cyclophosphamide Haplo-HSCT Revised: Peripheral Blood Stem Cell Graft and Sirolimus To Enhance Immune Reconstitution and Graft Versus Leukemia Effect In Patients With Active Leukemia. Blood, 2013, 122, 2118-2118.	1.4	2
107	Allogeneic Hematopoietic Stem Cell Transplantation For Severe Neuromyelitis Optica. Blood, 2013, 122, 5539-5539.	1.4	1
108	Incidence, Risk Factors and Clinical Outcome Of Leukemia Relapses Due To Loss Of The Mismatched HLA Haplotype After Partially-Incompatible Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 918-918.	1.4	1

#	Article	IF	Citations
109	High-Sensitivity Hematopoietic Chimerism By qPCR For Relapse Prediction and Specific Identification Of HLA Loss Leukemic Variants. Blood, 2013, 122, 3313-3313.	1.4	0
110	Modeling Antileukemic Adoptive Immunotherapy In Mouse-Humans Chimeras To Identify Novel Mechanisms Of Cancer Immunoediting. Blood, 2013, 122, 2017-2017.	1.4	1
111	Non-Linear Clonal Evolution Of Leukemia Driven By Selective Immune Pressure and Revealed By HLA Typing and High-Depth Exome Sequencing. Blood, 2013, 122, 1369-1369.	1.4	0
112	Treosulfan Based Myeloablative Regimen Provides High Rate Of Allogeneic Engraftment and Low Toxicity In Patients With Advanced Myelofibrosis,. Blood, 2013, 122, 5504-5504.	1.4	1
113	Intensification Of Treosulfan and Fludarabine-Based Conditioning With 4 Gy TBI For Allogeneic Stem Cell Transplantation In Patients With Hematological Malignancies. Blood, 2013, 122, 2149-2149.	1.4	0
114	Primary Bone Marrow Lymphoma. American Journal of Surgical Pathology, 2012, 36, 296-304.	3.7	59
115	T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood, 2012, 120, 1820-1830.	1.4	47
116	Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT. Blood, 2012, 119, 4813-4815.	1.4	42
117	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 2012, 119, 933-939.	1.4	260
118	Haploidentical Transplantation Outcome Is Not Inferior to Standard Matched Related and Unrelated Donor Transplantation: An Intention-to-Treat Analysis of 241 Patients with Acute Myeloid Leukemia. Blood, 2012, 120, 1920-1920.	1.4	1
119	Early Reconstitution of T-Cell Immunity to CMV After HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is a Strong Surrogate Biomarker for Lower Non-Relapse Mortality Rates. Blood, 2012, 120, 4191-4191.	1.4	28
120	Full Dose Treosulfan Based Reduced Toxicity Conditioning Regimen in Allogeneic Stem Cell Transplantation: Results in 123 Patients.. Blood, 2012, 120, 3139-3139.	1.4	0
121	Loss of Mismatched HLA At Leukemia Relapse After Hematopoietic Stem Cell Transplantation Is Significantly Associated with Clinical and Immunogenetic Hallmarks of Donor-Versus-Host Alloreactivity. Blood, 2012, 120, 1957-1957.	1.4	3
122	Improved Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Metastatic Renal Cancer Associated with Homozygosity for the HLA-G 14 Base-Pair Deletion Polymorphism: An EBMT STWP Study. Blood, 2012, 120, 4667-4667.	1.4	1
123	Evaluating CD8+ Memory Stem T Cells Dynamics After Allogeneic Bone Marrow Transplantation: Impact On GvHD Occurrence. Blood, 2012, 120, 4179-4179.	1.4	0
124	Evaluation of NIH-Defined Chronic Graft-Versus-Host-Disease in a Rapamycin-Based Haploidentical Stem Cell Transplantation: Analysis of 113 Consecutive Patients with High Risk Haematological Malignancies. Blood, 2012, 120, 4198-4198.	1.4	0
125	Unmanipulated Graft Transplantation From Family Haploidentical Donors: A Survey On 183 Adult Patients with Acute Leukemias On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2012, 120, 1987-1987.	1.4	0
126	Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia, 2011, 25, 1627-1631.	7.2	51

#	Article	IF	Citations
127	Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC). Journal of Cancer, 2011, 2, 347-349.	2.5	2
128	Combining allografting with mTOR inhibitors for metastatic renal cell cancer. Bone Marrow Transplantation, 2011, 46, 1586-1586.	2.4	1
129	Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft. Journal of Cancer, 2011, 2, 339-340.	2.5	12
130	Allogeneic hematopoietic stem cell transplantation in ovarian cancerâ€"the EBMT experience. International Journal of Cancer, 2010, 127, 1446-1452.	5.1	9
131	Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplantation, 2010, 45, 385-391.	2.4	53
132	Allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica, 2010, 95, 857-859.	3.5	26
133	Implementation of An Alternative Donor Option Is Prerequisite for a Good Intention-to-Treat (ITT) In Patients In Need of Allogeneic Transplantation: Analysis of 410 Patients. Blood, 2010, 116, 2382-2382.	1.4	0
134	Thymic Renewal and Anti-Leukemic Effect In Adults After Haploidentical Transplantation and Donor T Cell Suicide Gene Therapy. Blood, 2010, 116, 833-833.	1.4	0
135	Effect of Related and Unrelated Donor Haemopoietic Stem-Cell Transplantation on Outcome In Adults with High Risk Acute Leukemia: An Intention-to-Treat Analysis at a Single Center Institution. Blood, 2010, 116, 2385-2385.	1.4	17
136	Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplantation, 2009, 44, 237-242.	2.4	18
137	Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation. New England Journal of Medicine, 2009, 361, 478-488.	27.0	459
138	43-OR: Genomic loss of mismatched HLA in leukemia is a major mechanism of in vivo escape from T cell immunosurveillance following haploidentical hematopoietic stem cell transplantation. Human Immunology, 2009, 70, S167.	2.4	0
139	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase Iâ€"II study. Lancet Oncology, The, 2009, 10, 489-500.	10.7	458
140	Interleukin-10 Anergized Donor T Cell Infusion Improves Immune Reconstitution without Severe Graft-Versus-Host-Disease After Haploidentical Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 45-45.	1.4	12
141	Rapamycin-Based GvHD Prophylaxis Is Effective in T-Cell Replete Unmanipulated Haploidentical Peripheral Stem Cell Transplantation for Advanced Haematological Malignancies: Results in 46 Patients.. Blood, 2009, 114, 666-666.	1.4	0
142	Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors. Leukemia, 2008, 22, 2119-2122.	7.2	12
143	Pre-transplant18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leukemia and Lymphoma, 2008, 49, 727-733.	1.3	27
144	Temporal, quantitative, and functional characteristics of single-KIRâ€"positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood, 2008, 112, 3488-3499.	1.4	113

#	Article	IF	Citations
145	Genomic Loss of the Mismatched HLA Locus in Leukemia Is a Major Mechanism of in Vivo Escape from T Cell Immunosurveillance Following Haploidentical HSCT. Blood, 2008, 112, 828-828.	1.4	4
146	Early and Effective Immune-Recovery by Gene-Engineered Lymphocytes after Haploidentical Transplantation for Leukemia Abate Late Transplant Mortality. Blood, 2008, 112, 353-353.	1.4	0
147	Antitumor effects of HSV-TKâ€“engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood, 2007, 109, 4698-4707.	1.4	171
148	Bortezomib after Allografting in Multiple Myeloma: Association between Neurotoxicity and Cyclosporine Treatment. Biology of Blood and Marrow Transplantation, 2007, 13, 497-499.	2.0	5
149	Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells. Journal of Translational Medicine, 2007, 5, 35.	4.4	7
150	The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology, 2006, 48, 529-535.	2.9	14
151	Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. Bone Marrow Transplantation, 2006, 37, 311-315.	2.4	2
152	Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Annals of Oncology, 2006, 17, 1134-1140.	1.2	84
153	Rapid and Wide Immunereconstitution Obtained with HSV-TK Engineered Donor Lymphocyte Add-Backs Permits Long-Term Survival after haplo-HSCT.. Blood, 2006, 108, 307-307.	1.4	4
154	Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica, 2006, 91, 837-9.	3.5	38
155	Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer, 2005, 104, 2099-2103.	4.1	50
156	Incidence of Human Cytomegalovirus Infection in Patients with Refractory Solid Tumors Receiving Nonmyeloablative Allogeneic Stem Cell Transplants versus Recipients of Standard SCT for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2005, 11, 423-428.	2.0	5
157	Allogeneic stem cell transplantation for the treatment of advanced solid tumors. Seminars in Immunopathology, 2004, 26, 95-108.	4.0	18
158	Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood, 2002, 99, 4234-4236.	1.4	209
159	Allogeneic Non-Myeloablative Peripheral-Blood Stem Cell Transplant in Solid Tumors. Tumori, 2002, 1, S32-S33.	1.1	3
160	Pulmonary lymphangioleimoyomatosis and renal papillary cancer: incomplete expression of tuberous sclerosis?. Nephrology Dialysis Transplantation, 1997, 12, 2740-2743.	0.7	6